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Abstract 
      Alzheimer’s disease (AD) is a debilitating neurodegenerative disease 
with no known cure.  The cause and progression of AD is still unclear.  
Over the years, studies have shown that one of the earliest cytotoxic 
effects is the production of reactive oxygen species (ROS) and 
inflammation induced by the amyloid-β peptide in microglial cells, 
endothelial cells and neurons.  The focus of this thesis is to study the 
effects of Azelnidipine (ALP), which is a Calcium channel blocker, on Aβ-
induced oxidative stress and its downstream pathways in mouse 
immortalized cerebral endothelial cells (bEnd.3). In AD, Aβ1-42 induces 
oxidative stress through the activation of ERK 1/2 pathway, 
phosphorylation of cPLA2 and production of intercellular superoxide 
anions.  Furthermore, Aβ42 has been shown to induce the translocation 
of NF-κB into the nucleus of bEnd.3 cells causing an inflammatory 
response.  Here, ALP is utilized to reduce the ROS and inflammatory 
effects of Aβ42 in bEnd.3 cells.  The results show that ALP is effective in 
reducing the Aβ42 induced superoxide anion production, ERK 1/2 
activation, cPLA2 phosphorylation and NF-κB translocation into the 
nucleus of bEnd.3 cells.  Thus, ALP may be an effective treatment to 
alleviate the debilitating effects of AD.  Finally, this research implicates 
that there may be cross-talk between the ERK 1/2 pathway and NF-κB 
translocation into the bEnd.3 nucleus.
vii 
 
Chapter 1 Introduction 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease 
first discovered by German physician and neuropathologist Alois 
Alzheimer in 1906(Berchtold & Cotman, 1998).  AD is the most common 
form of dementia and is characterized by the spontaneous misfolding of 
proteins, specifically Amyloid-β (Aβ), into amyloid plaques (micrometer 
scale) and oligomers (nanometer scale) (Chiti & Dobson, 2006, Jan et 
al., 2010, Karran et al., 2011, Selkoe, 2000b).  In the case of AD, 
amyloid structures form in the brain and inhibit cellular function by 
blocking neuron synapsis, which eventually results in death (Kim et al., 
2013, Lacor et al., 2007, Lauren et al., 2009).  There is no known drugs 
targeting Aβ showed positive results in clinical trials yet (Morris, 2013).  
AD is a widespread disease that affects approximately 5.2 million 
Americans annually, with the vast majority being age 65 or older, 
according to the latest estimates in 2014 (Hebert et al., 2013) 
(Association, 2006;2014).  Over the last few decades modern medicine 
has increased the average life expectancy and as a result, AD is one of 
the few diseases that has increased in occurrences and fatalities over 
the same time span (Association, 2006) (Minino et al., 2002, Murphy et 
al., 2013). Worldwide, in 2006 there were 26.6 million people with AD 
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which is expected to increase to affect 1 in 85 people by 2050 
(Brookmeyer et al., 2007). 
 
1.2 Amyloid-β peptide 
Although the pathogenesis is still unclear, people believe that the 
Amyloid-β peptide (Aβ) is responsible for AD progression.  One 
hypothesis is that the dementia like symptoms of AD arise from the  
deposition and aggregation of Aβ into plaques (Selkoe, 2000a, Hardy & 
Selkoe, 2002) (Stalder et al., 1999, Dickson, 1999, Frautschy et al., 
1998, Selkoe, 2000a). 
Aβ is derived from the amyloidogenic pathway processing of amyloid 
precursor protein (APP) which involves β-secretase (Vassar, 2004). APP 
is an integral membrane protein concentrated in the synapse of neurons 
but expressed in many tissues, it is reported to have a role in cell 
adhesion (Sosa et al., 2013).  APP is cleaved and processed by secretase 
enzymes into two pathways, the non-amyloidogenic and amyloidogenic 
pathway. Under the non-amyloidogenic pathway, which is the normal 
cleavage pathway, APP is first cleaved by α-secretase into soluble APPα 
(sAPPα) and the carboxy-terminal fragment C83 at a site inside the Aβ 
sequence domain. C83 is then cleaved by γ-secretase into P3 and the 
APP intracellular domain (AICD C57/59) (Thathiah & De Strooper, 2011). 
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Under the amyloidogenic pathway, also known as the abnormal cleavage 
pathway, APP is cleaved by β-secretase forming sAPPβ and the carboxy-
terminal fragment C99, followed by γ-secretase cleavage and produce 
AICD (C57/59), Aβ40, Aβ42 or other Aβ isoforms (King & Scott Turner, 
2004, Koo, 2002, Reinhard et al., 2005). sAPPα has been found to have 
neuroprotective and neuritotrophic properties (Chen & Yankner, 1991, 
Jin et al., 1994, Mattson et al., 1993, Schubert et al., 1989, Furukawa 
et al., 1996a, Han et al., 2005, Ma et al., 2009). It is also shown that 
sAPPα regulates the proliferation of embryonic and adult neural stem 
cells as a growth factor (Caille et al., 2004, Ohsawa et al., 1999). In 
vivo studies indicate that sAPPα alone has the ability to eliminate the 
abnormalities of APP deficient mice (Ring et al., 2007). Unlike sAPPα, 
sAPPβ does not have neuroprotective effects (Furukawa et al., 1996a, 
Furukawa et al., 1996b). The AICDs are quickly degrade after γ-
cleavage, but it forms a stable complex with Fe65 and Tip60, this 
complex promotes the gene expression of such as KAI1, Neprilysin, 
LRP1, p53, GSK-3β and EGF receptor (Alves da Costa et al., 2006, Baek 
et al., 2002, Cao & Sudhof, 2004, Kim et al., 2003, Liu et al., 2007, 
Pardossi-Piquard et al., 2005, Zhang et al., 2007). 
Among all Aβ peptides, Aβ40 is abundantly produced in both healthy and 
AD patients’ brains, whereas other forms of Aβ are produced at lower 
levels, including Aβ37, Aβ38, Aβ42 and Aβ43 (Benilova et al., 2012). Aβ42 
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is suggested to be the most toxic form, and the ratio of Aβ42/Aβ40 is 
considered to be a biomarker for AD diagnosis (Klein et al., 1999, 
Kuperstein et al., 2010, Spies et al., 2010, Wiltfang et al., 2007). Both 
Aβ40 and Aβ42 peptides attempt to self-aggregate, but Aβ42 is more likely 
to aggregating from its monomer form into higher molecular weight 
forms, such as Aβ-derived diffusible ligand (ADDL), low-molecular 
weight oligomers, oligomers, protofilaments, fibrils and plaques (Cleary 
et al., 2005, Jan et al., 2010, Mucke et al., 2000, Resende et al., 2008, 
Walsh et al., 2002, Westerman et al., 2002). Different species of Aβ42 
show different biological effects, studies show that the oligomer form of 
Aβ is believed to be more neurotoxic than the monomer or fibril form 
(Resende et al., 2008, Walsh & Selkoe, 2007), whereas Aβ dimmers and 
trimmers are toxic to synapses (Klyubin et al., 2008, Walsh et al., 2005, 
Benilova et al., 2012).  
 
1.3 Reactive Oxygen Species 
Cells in the central nervous system (CNS) are highly sensitive to 
oxidative stress due to the high oxygen consumption within the brain. 
Oxidative stress is reported to be involved in a number of 
neurodegenerative disease, including AD (Coyle & Puttfarcken, 1993, 
Emerit et al., 2004). Numerous studies have demonstrated that 
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oxidative stress in cerebral vasculature and astrocytes is induced by 
vascular deposition of Aβ (Abramov & Duchen, 2005, Cai et al., 2003). 
Reactive oxygen species (ROS) play an important role in the modulation 
of cellular metabolic pathways under normal conditions (Suzuki et al., 
1997). When over produced, which is associated with Aβ-induced 
oxidative stress (Girouard & Iadecola, 2006, Park et al., 2008, Sim et 
al., 2005), ROS becomes harmful and causes Aβ-induced cytotoxic 
effects (Butterfield et al., 2001, Sultana & Butterfield, 2010). 
 
1.4 ERK 1/2 and cPLA2 
Aβ has been shown to induce cytotoxic effects that alter the activation 
of extracellular signal-regulated kinase 1/2 (ERK 1/2) which are also 
known as mitogen-activated protein kinase 3 (MAPK3), MAPK 1 cascade. 
Also, Aβ was reported to induce the phosphorylation of cytosolic 
phospholipase A2 (cPLA2) (Dineley et al., 2001, McDonald et al., 1998, 
Moses et al., 2006, Shelat et al., 2008, Stephenson et al., 1996, Young 
et al., 2009, Zhu et al., 2006).  ERKs are widely expressed protein 
kinase intracellular signaling molecules. The ERK pathway can be 
activated by many different stimuli, such as growth factors, cytokines, 
virus infection etc. ERKs can activate many transcription factors (Rao & 
Reddy, 1994) and some downstream protein kinases, including cPLA2 
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phosphorylation (Askarova et al., 2011b, Lee et al., 2011, Zhu et al., 
2009). 
Phospholipases A2 (PLA2s) are enzymes that catalytically hydrolyze the 
sn-2 acyl bond of phospholipids and release arachidonic acid (Murakami 
& Kudo, 2002, Sun et al., 2004), which is converted into active 
compounds called eicosanoids by downstream modification of 
cyclooxygenases. Eicosanoids are signaling molecules classified as anti-
inflammatory and inflammatory mediators (Dennis, 1994). PLA2s 
enzymes currently consists of 15 groups and many subgroups, but 
mainly categorized into three major families: secreted PLA2s (sPLA2), 
the cytosolic PLA2s (cPLA2) and calcium-independent PLA2s (iPLA2) 
(Schaloske & Dennis, 2006). It is reported that overproduction of cPLA2 
is involved in many neurodegenerative diseases, including AD 
(Stephenson et al., 1996, Sun et al., 2007). 
 
1.5 Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) is a protein complex that controls transcription of DNA. NF-κB is 
found to be involved in cellular responses stimulated by stress, 
cytokines, free radicals, ultraviolet irradiation, oxidized LDL and 
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bacterial or viral antigens (Tian & Brasier, 2003, Perkins, 2007, Gilmore, 
2006, Brasier, 2006, Gilmore, 1999). NF-κB has also been reported to 
be involved in process of synaptic plasticity and memory (Levenson et 
al., 2004, Albensi & Mattson, 2000, Merlo et al., 2002, Freudenthal et 
al., 1998, Meffert et al., 2003). NF-κB complex contains two subunits, 
class I protein like p50 and p52 and class II protein like RelA (p65), RelB 
and c-Rel (Nabel & Verma, 1993). In unstimulated cells, NF-κB dimers 
are sequestered in the cytoplasm by its inhibitor, IκBs (Inhibitor of κB), 
it covers the nuclear localization signals (NLS) of NF-κB to keep it in an 
inactive state in the cytoplasm (Jacobs & Harrison, 1998). Upon stimuli, 
the IκB proteins are degraded by IκB kinase (IKK), then NF-κB complex 
is free and translocates to the nucleus for gene expression. 
 
1.6 Azelnidipine 
Azelnidipine (ALP) (Fig. 1.1) is a dihydropyridine calcium channel 
blocker that has a long-lasting hypotensive effect (Oizumi et al., 1989). 
Studies suggest that dihydropyridine (DHP) compounds such as ALP 
facilitate Aβ1-42 clearance across the blood-brain barrier (BBB) 
(Bachmeier et al., 2011). Also, Azelnidipine is reported to have anti-
inflammatory and neuroprotective effects (Kurobe et al., 2013, Omote 
et al., 2014). Evidence suggests that ALP may inhibit inflammatory 
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responses triggered by different stimuli, such as TNF-α, through its anti-
oxidative properties (Matsui et al., 2005, Ohyama et al., 2012, 
Yamagishi et al., 2004).   Here we investigate the effects of ALP on the 
aforementioned proteins and processes shown to be associated with Aβ-
induced cytotoxic effects in AD progression (ROS production and 
inflammation).  The results indicate that ALP reduces the inflammation 
and ROS effects of Aβ buildup within the human brain.  Thus, ALP may 
be a treatment option to alleviate the debilitating effects of AD.  
 
 
Figure 1.1 Chemical Structural of Azelnidipine 
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Chapter 2 Materials and Methods 
2.1 Chemicals and Regents 
    Dulbecco’s Modified Eagle Medium with phenol red and high glucose 
(1X) (DMEM) (A14431), Rat Primary Cortical Astrocytes (N7745-100), 
0.25% or 0.05% Trypsin-EDTA (1X) (25200-056), Dulbecco’s 
Phosphate Buffered Saline without Calcium Chloride or Magnesium 
Chloride (1X) (DPBS) (14190-144), Penicillin-Streptomycin (5,000 
Units/ml) (P/S) (15070-063), Dulbecco’s Modified Eagle Medium without 
phenol red (1X) (DMEM w/o phenol red) (31053-028) and UltraPure™ 
10% Sodium Dodecyl Sulfate Solution (10% SDS) (15553-035) are from 
Life Technologies (Carlsbad, CA, USA). Fetal Bovine Serum (FBS) 
(F6178-500ml), Dimethyl Sulfoxide Hybri-max (DMSO) (D2650), 
Dihydroethidium (DHE) (37291-25MG), Azelnidipine (ALP) (A7106-
10MG), 1, 1, 1, 3, 3, 3-Hexafluoro-2-propanol (HFIP) (Fluka) (52517), 
Triton® X-100 (X100-100ML), Paraformaldehyde (powder, 95%) (PFA) 
(158127-500G), Hoechst 33258 (861405-100MG), Agarose (A9539-
50G) and β-actin antibody are from Sigma-Aldrich (St. Louis, MO, USA). 
bEnd.3 Mouse Cerebral Endothelial Cell Line (bEnd.3) (ATCC CRL-2299) 
is from American Type Culture Collection (ATCC, Manassas, VA, USA). 
Bovine Serum Albumin (Fraction V) (BP1605-100), Glycerol (G33-1) and 
Methanol (A413-4) are from Thermo Fisher Scientific (Hampton, NH, 
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USA). Beta-Amyloid (1-42) (Human) (20276) is from Anaspec (Fremont, 
CA, USA). Ham’s F12 (without phenol red) (226-057-12) is from 
Crystalgen (Long Island, NY, USA). NF-κB p65 (c-20) Antibody (SC-372) 
is from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-Rabbit IgG 
Fab2 Alexa Fluor 488 Molecular Probes (4412s), Phosphate Buffered 
Saline (PBS-20X) (9808), 3X Blue Loading Buffer (3X Blue Loading 
Buffer & 30X Dithiothreitol (DTT)) (7722s), Protease/Phosphatase 
Inhibitor Cocktail (100X) (5872s), Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (197G2), Rabbit Monoclonal Antibody (Phos-ERK1/2) 
(4377), p44/42 MAPK (Erk1/2) (3A7), Mouse Monoclonal Antibody 
(ERK1/2) (9107), Phospho-cPLA2 (Ser505) Antibody (cPLA2) (2831), 
cPLA2 Antibody (cPLA2) (2832), Anti-Rabbit IgG, HRP-linked Antibody 
(7074s) and Anti-Mouse IgG, HRP-linked Antibody (7076P2) are from 
Cell Signaling Technology (CST, Danvers, MA, USA). Recombinant 
Mouse (E. coli-derived) Tumor Necrosis Factor-α (TNF-α) (aa84-235) 
(410-TRNC) is from R&D systems™ (Minneapolis, MN, USA). Resolving 
Gel Buffer (1.5M Tris-HCl buffer, pH 8.8) (161-0798), Stacking Gel 
Buffer (0.5M Tris-HCl buffer, pH 6.8) (161-0799), 30% Acrylamide/Bis 
Solution (37.5:1) (161-0158), 10X Tris Buffered Saline (170-6435), 
Tween 20 (170-6531), Nitrocellulose Membrane (0.45 μm) (162-0115), 
10X Tris/Glycine/SDS Buffer (TGS buffer) (161-0772) and 10X 
Tris/Glycine Buffer (TG buffer) (61-0771) are from Bio-RAD Laboratories 
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(Hercules, CA, USA). Non-fat Dried Milk Powder (A0830, 1000) is from 
AppliChem (Gatersleben, Saxony-Anhalt, Germany). Restore™ Western 
Blot Stripping Buffer (21059), Ammonium Persulfate (APS) (17874), 
Tetramethylenediamine (TEMED) (17919), SuperSignal® West Pico 
Chemiluminescent Substrate (Pico) (34080) and SuperSignal® West 
Femto Maximum Sensitivity Substrate (Femto) (34095) are from 
Thermo Scientific (Waltham, MA, USA). 
 
2.2 Cell Culture 
2.2.1 Rat Primary Cortical Astrocytes 
    Rat primary cortical Astrocytes were seeded into T25 cell culture flask 
(Corning, NY, USA) with cell culture medium (15% FBS (v/v), 1% P/S 
(v/v), DMEM) at a ratio of 1:9, totally 10ml diluted cell solution was 
seeded into each T25 cell culture flask. The cells were maintained at 
37°C in a 5% CO2 humidified incubator, cell culture medium was 
changed every other day and cells were sub-cultured into another T25 
cell culture flask before reaching confluence. Briefly, cells were washed 
with pre-warmed PBS for twice, 2 ml 0.05% Trypsin/EDTA solution was 
added into each T25 cell culture flask and incubated in the incubator for 
2-5 minutes, cells were then observed under a microscope to see 
whether detached from the substrate of the flask. After detaching, 8ml 
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cell culture medium was added into the flask to stop the reaction. Cell 
solution was then diluted with cell culture medium with a ratio of 2:8 
and then added into a new T25 cell culture flask and maintained in the 
incubator. For experiment, cells were sub-cultured into dishes with the 
same dilution ratio. Only three passages of Astrocytes were used for 
experiments. 
 
2.2.2 bEnd.3 Mouse Cerebral Endothelial Cells 
Passage 21 bEnd.3 mouse cerebral endothelial cell line was 
purchased from ATCC. Cells were seeded into T25 cell culture flask after 
thawing in a 37°C water bath. 9 ml cell culture medium (10% FBS (v/v), 
1% P/S (v/v), DMEM) was then added into the flask. Cell culture medium 
was changed every two to three days. After confluence, cells were 
washed twice with pre-warmed DPBS, 2ml 0.25% Trypsin/EDTA solution 
was added into the flask, and the flask was incubated for 2-3 minutes 
until cells were fully detached.  8ml freeze medium (95% cell culture 
medium, 5% DMSO (v/v)) was added into the flask after cells detached. 
1ml cell-freeze medium solution was then added into each “O” ring 
cryopreservation vials. The vials were put into a Nalgene® Mr. Frosty™ 
Cryo 1°C freezing container (Rochester, NY, USA) (5100-001) which 
was then placed in the -80°C refrigerator for at least 4 hours to achieve 
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a -1°C/min. rate of cooling. After cooling down, cryopreservation vials 
were stored in a liquid nitrogen tank for long-term storage. 
Passage 22 (P.22) bEnd.3 cell line were used for experiments. Cells 
were seeded into T25 cell culture flasks with cell culture medium (10% 
FBS, 1% P/S, DMEM). The flasks were maintained at 37°C in a 5% CO2 
humidified incubator, cell culture medium was changed every two to 
three days. Before confluence, cells were sub-cultured into a new T25 
cell culture flask. For experiments, cells were also sub-cultured into 
dishes, 6-well or 12-well plates. 
 
2.3 Preparation of Aβ1-42. 
1 mg powdered Aβ1-42 peptide was dissolved in 220µl of HFIP, 
solution was milk-like now. The vial containing dissolved Aβ1-42 was 
vortexed for 5 minutes, wrapped with Aluminum foil and placed under a 
hood for 1 hour. The Aβ1-42-HFIP solution became transparent after 1 
hour. Afterwards, 10µl of Aβ1-42 was aliquoted into 20 Eppendorf tubes. 
Then, HFIP in each tube was removed by placing tubes in a speed 
vacuum apparatus for exactly 1 hour. After 1 hour, tubes were removed 
from the speed vacuum, sealed with Parafilm® and stored at -20°C until 
use. Normally, Aβ1-42 was freshly made every month. 
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When used, the Aβ1-42 film was resuspended in 2μl DMSO and 
sonicated for 5 minutes with a VWR® sonicator (Radnor, PA, USA).  98 
μl DPBS was then added into the tube and vortexed for 60 seconds.  The 
100 µM concentration of the Aβ1-42 solution was now 100μM. Tube was 
then incubated at 4°C for 45-48 hours to allow oligomerization. The 
solution was then further diluted in treating medium (1% BSA (w/v), 
DMEM) to a final concentration of 1μM or 5μM for treatments. 
 
2.4 Preparation of Azelnidipine 
Azelnidipine was aliquoted into Eppendorf tubes and scaled, the 
weight of Azelnidipine in each tube was recorded for further calculation. 
Azelnidipine was first dissolved in 1 ml DMSO (solution A). Then, 10μl 
solution A was added into 990 μl treating medium (1% BSA, DMEM) 
(Solution B).  Solution B was added to 10 ml or 20 ml of treating medium 
to make a final concentration of 20 nM (Final solution). This final solution 
was used for cell pre-treatment. 
 
2.5 Reactive Oxygen Species (ROS) Measurement 
To quantify superoxide anion production induced by Aβ1-42 and 
suppressed by Azelnidipine in astrocytes or bEnd.3 mouse cerebral 
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endothelial cells, cells were starved for 12 hours in DMEM, followed by 
pre-treatment with 20 nM Azelnidipine for 4 hours. After pre-treatment, 
cells were treated with 5 μM Aβ1-42 and 20 μM DHE for 2 hours. DHE 
was first dissolved in DMSO and further diluted in phenol red DMEM to 
achieve the desired final concentration. 
Fluorescent intensity of DHE was measured at room temperature 
using a Nikon TE-2000U fluorescence microscope (Tokyo, Japan) with a 
20X objective lens. For each dish, 20 bright field images and 20 DHE 
fluorescence images were acquired using a CCD camera from 
Photometrics (Turson, AZ) controlled by a PC running MetaVue imaging 
software v6.2r6 (Universal Imaging, PA). Fluorescent intensity of DHE 
per cell was measured by dividing image fluorescent intensity by cell 
number of the image.  Prior to data analysis, the background was 
subtracted from all images and the threshold was used for each image 
as further background subtraction.  The threshold level was maintained 
for all images within the same experiment. 
 
2.6 NF-κB Translocation Measurement 
For quantification of translocation of NF-κB, immunofluorescent 
technology was employed.  Cells were sub-cultured into 12-well plates 
containing pre-coated coverslip each well. After reaching 70-80% 
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confluence, cells were starved for 12 hours and pre-treated with 20 nM 
Azelnidipine for 4 hours.   Cells were then treated with 5 μM Aβ1-42 or 
100 ng/ml TNF-α for 2 hours, fixed with 3.7% PFA (w/v) for 15 minutes 
with rotation, permeabilized by incubating with 0.1% Triton® X-100 
(v/v) for 8 minutes, blocked with 5% BSA (w/v) in DPBS for 1 hour, and 
then incubated with NF-κB p65 (C-20) rabbit polyclonal IgG primary 
antibody (1:50 dilution, diluted in 1% BSA in DPBS) overnight for NF-
κB staining. After approximately 16 hours, cells were incubated with 
anti-rabbit IgG (H+L), F(ab’)2 fragment (Alexa Fluor® 488 conjugate) 
secondary antibody (1:1000 dilution, diluted in 1% BSA in DPBS) for 1 
hour.  The cell nuclei were then stained with Hoechst 33258 (2 µg/ml, 
diluted in DPBS) for 10 minutes. Between each step, cells were washed 
with DPBS for 3-5 minutes.  After staining, coverslips were allowed to 
stay in a dark room for approximately 20 minutes to dry.  Then each 
coverslip was mounted onto a glass slide and sealed with nail polish. 
Images were acquired within two days. 
Fluorescent images of NF-κB and nucleus were acquired using the 
same Nikon microscope as earlier with a 60X objective.  Twenty images 
of NF-κB and nucleus were taken, respectively. Background subtraction 
was done before image acquirement. To quantify NF-κB translocation, 
total image intensity (ITotal) and nuclear intensity (INucleus) of NF-κB 
p65 were measured for each fluorescent image.  Nuclear intensity 
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divided by total intensity (INucleus/ITotal) was used to represent NF-κB 
translocation. 
 
2.7 Western Blot Analysis 
Western blot analysis was employed to measure ERK 1/2 or cPLA2 
phosphorylation. Cells were sub-cultured onto a 6-well plates and the 
experiment was carried out when cells reached 90% confluence.  For 
treatments, cells were starved for 24 hours before being pre-treated 
with 20 nM Azelnidipine for 4 hours, followed by 5 µM Aβ1-42 treatment 
for 15 minutes or 30 minutes for measurement of phosphorylation of 
ERK 1/2 or cPLA2, respectively. After treatments, cells were washed with 
pre-warmed DPBS twice and lysed by blue loading buffer (62.5 mM Tris-
HCl (pH 6.8 at 25°C), 2% (w/v) SDS, 10% glycerol, 0.01% (w/v) 
bromophenol blue, 41.7 mM Dithiothreitol, Aprotinin, Bestatin, E64, 
Leupeptin, β-glycerophosphate, sodium pyrophosphate and sodium 
orthovanadate).  Cells were collected from the 6-well plates, put into 
Eppendorf tubes and immediately placed on ice to prevent protein 
degradation.  Samples were then sonicated for 10 seconds three times, 
micro centrifuged for 10 seconds and boiled for 5 minutes at 95°C.  After 
cooling down, samples were stored at -20°C for further experimentation. 
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After thawing, equivalent amounts of 40 μl samples were subjected 
to electrophoresis in 10% SDS-polyacrylamide gels, and transferred to 
0.45 μM nitrocellulose membranes.  Membranes were blocked in 5% 
(w/v) non-fat milk in Tris-buffer saline containing 0.1% (v/v) Tween 20 
(TBST) for 1 hour and then incubated overnight at 4°C with primary 
antibodies in 5% (w/v) BSA or 5% (w/v) non-fat milk in TBST with 
dilution ratio in accordance with the antibody datasheet, p-cPLA2 or 
cPLA2 antibodies (1:1000 dilution), p-ERK1/2 (1:1000 dilution) or ERK 
1/2 (1:2000 dilution) antibodies and β-actin antibody (1:50,000 
dilution). Membranes were washed 5 minutes three times and incubated 
with horseradish peroxidase conjugated anti-rabbit IgG (H&L), antibody 
(1:3000 dilution) or horseradish peroxidase conjugated anti-mouse IgG 
(H&L) antibody (1:5000 dilution) in 5% (w/v) non-fat milk in TBST at 
room temperature for 1 hour. After washing for 5 minutes three times 
with TBST, the membrane was subjected to Pico or Femto 
Chemiluminescent detection reagents to visualize bands.  Bands were 
detected by blue autoradiography film or Fuji LAS-3000 image reader 
(GE Healthcare, Piscataway, NJ, USA). Bands intensity were quantified 
using a computer running Quantity One software v4.6.6 (Bio-Rad, 
Hercules, CA, USA).  For re-incubation with antibodies, membranes 
were stripped with Restore™ Western Blot Stripping Buffer for 20 
minutes and washed for 5 minutes (x6) with TBST. After washing, 
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membranes were good for re-incubation with antibodies, each 
membrane was stripped no more than twice. 
 
2.8 Statistical Analysis 
    The data is presented as the mean ± standard deviation (SD) from 
at least three trials of a given experiment.  Analysis was carried out with 
student-t test utilizing KaleidaGraph. Values of p < 0.05 are considered 
statistically significant. 
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Chapter 3 Results 
3.1 Azelnidipine Suppresses Aβ-induced Superoxide 
Production in Both Primary Astrocytes and bEnd.3 Cells 
In order to investigate the effects of ALP on Aβ-induced superoxide 
production and determine the working concentration of ALP, intercellular 
ROS’s of rat primary cortical astrocytes and mouse cerebral endothelial 
cells (bEnd.3 cell line) were fluorescently labeled with DHE. Astrocytes 
and bEnd.3 cells were exposed to the oligomer form of Aβ1-42 for 2 hours 
as a control which showed an increase in superoxide anions with respect 
to the cells pre-treated with 20 nM ALP or cells without treatment 
(Figures 3.1 and 3.2) (Figure 3.2 contributed by Andrey Tsoy).  Figures 
3.1a and 3.1b show the effect of ALP on the astrocytes is concentration 
dependent.  A 20 nM pre-treatment of ALP proved to be the most 
effective at preventing the superoxide production induced by Aβ1-42 with 
lower ALP concentrations (10 nM) being ineffective and higher ALP 
concentrations (100 nM) inducing its own ROS production.  When pre-
treated with 20 nM ALP the Aβ1-42 induced superoxide production was 
reduced 25% and 52% for astrocytes and endothelial cells, respectively, 
when compared to the 5 µM Aβ1-42 positive control sample. (Figures 3.1a 
and 3.2)  Therefore, 20 nM ALP was used for the subsequent 
experiments.  
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Figure 3.1 Effect of ALP on Aβ-induced ROS production in astrocytes 
a) Astrocytes were treated with two concentrations of ALP (10 and 20 nM), 5 µM Aβ1-42, both 
ALP and Aβ1-42 or neither compound (Control) to yield a total of six data sets.  b) Astrocytes 
were pre-treated with 200 nM ALP, treated with 5 µM Aβ1-42, both ALP and Aβ1-42 or neither 
compound (Control) to yield a total of 4 data sets. c) Representative fluorescent images of DHE 
ROS intensity. ROS production was quantified by measuring the DHE intensity within each 
sample.  The data is expressed as a fraction percentages of the control group with the mean ± 
SD from three independent experiments reported (** p<0.01, *** p<0.001, comparing with 
control group) (o p<0.05, oo p<0.01, comparing with 5 µM Aβ1-42 treatment only group). 
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 Figure 3.2 Effect of ALP on Aβ-induced ROS production in bEnd.3 mouse cerebral 
endothelial cells 
bEnd.3 cells were treated with 20 nM ALP, 5 μM Aβ1-42, both ALP and Aβ1-42 or neither compound 
(Control) to yield a total of 4 data sets. ROS production was quantified by measuring the DHE 
intensity within each sample. The data is expressed as a fraction percentages of the control 
group with the mean ± SD from three independent experiments reported (** p<0.01, *** p< 
0.001, comparing with control group) (ooo p<0.001, comparing with 5 μM Aβ1-42 treatment only 
group) (Data contributed by Andrey Tsoy). 
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3.2 Azelnidipine Suppresses Aβ-induced Phosphorylation 
of ERK 1/2 in bEnd.3 Cells 
In an effort to determine the most effective method for studying how 
Aβ1-42 contributes to ERK p42 and p44 phosphorylation, bEnd.3 cells 
were starved over a 24 hour period and phosphorylated ERK (p-ERK) 
p42/p44 levels were measured periodically.  The data for both ERK p42 
and ERK p44 showed an initial increase in activation (5 minutes) and an 
immediate suppression thereafter to reach a minimum at 30 minutes 
(Figure 3.5 & Figure 3.6).  Both systems continued to suppress ERK 1/2 
phosphorylation up to 24 hours. A 24 hour starvation time was used for 
subsequent experiments due to the low expression of p-ERK p42 and 
p44. 
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 Figure 3.3 Starving time study on ERK p42 phosphorylation in bEnd.3 cells 
bEnd.3 cells were starved over a 24 hour period and p-ERK p42 level was measured periodically. 
Protein expression level was quantified by western blot analysis. The data is expressed as a 
fraction percentages of the control group withbox plot from three independent experiments 
reported. (* p<0.05, ** p<0.01, *** p<0.001, comparing with non-starving group). 
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Figure 3.4 Starving time study on ERK p44 phosphorylation in bEnd.3 cells 
bEnd.3 cells were starved over a 24 hour period and p-ERK p44 level was measured periodically. 
Protein expression level was quantified by western blot analysis.  The data is expressed as a 
fraction percentages of the control group with box plot from three independent experiments 
reported. (* p<0.05, *** p<0.001, comparing with non-starving group). 
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To assess the effects of Aβ1-42 on ERK 1/2 phosphorylation a similar 
time-course study was carried out.  bEnd.3 cells were treated with Aβ1-
42 for a period of 22 hours where p-ERK levels were measured 
periodically. Phosphorylation ratio of ERK p42 was quantified by dividing 
p-ERK p42 intensity by total ERK p42 intensity (shown as normalized by 
total) or subsequently divided by β-actin intensity (shown as normalized 
by β-actin) (Figure 3.7 & Figure 3.8). β-actin served as loading control, 
which shows that the loading procedure of western blot analysis had a 
minimum influence on quantitative results (Figure 3.7 & Figure 3.8). The 
results revealed that bEnd.3 cells treated with Aβ1-42 produced more p-
ERK p42 compared to the control group cells which did not receive any 
Aβ1-42 treatment with a maximum increase of 1.7-fold at 15 minutes 
(Figure 3.7). Aβ1-42 treatment induced similar phosphorylation of ERK 
p44 where p-ERK p44 reached a maximum at 15 minutes which was 2 
times greater than the previous time point (Figure 3.8).  Future bEnd.3 
cells were treated with Aβ1-42 for 15-minutes to induce the maximum p-
ERK p42/p44 expression. 
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Figure 3.5 Aβ treatment time course study on ERK p42 phosphorylation in bEnd.3 
cells 
bEnd.3 cells were treated with 5 μM Aβ1-42 over a 22 hour period, p-ERK p42 level was measured 
periodically. The phosphorylation ratio of ERK p42 was quantified by dividing p-ERK p42 intensity 
by total ERK p42 intensity (shown as normalized by total) or subsequently divided by β-actin 
intensity (shown as normalized by β-actin). Protein expression level was measured by western 
blot analysis. The data is expressed as true values from a single trial. 
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Figure 3.6 Aβ treatment time course study on ERK p44 phosphorylation in bEnd.3 
cells 
bEnd.3 cells were treated with 5 μM Aβ1-42 over a 22 hour period, p-ERK p44 level was measured 
periodically. Protein expression level was quantified by western blot analysis. The data is 
expressed as true values from a single trial. 
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To investigate effects of ALP on Aβ-induced ERK 1/2 phosphorylation, 
four bEnd.3 cell treatment groups were used; a control group without 
treatment, Aβ group with 5 µM Aβ1-42 treatment for 15 minutes, ALP + 
Aβ1-42 group with pretreatment of 20 nM ALP for 4 hours and treatment 
of 5 µM Aβ1-42 for 15 minutes and ALP group with 20 nM ALP 
pretreatment for 4 hours.  A 1.3-fold increase of p-ERK p42 expression 
was observed for the Aβ1-42 group but not the groups with ALP treatment 
when compared to the control group (Figure 3.9).  Similarly, a 2.4-fold 
increase was observed for p-ERK p44 expression within the Aβ1-42 group 
but not the groups with ALP treatment when compared to the control 
group (Figure 3.10). The results clearly indicate that ALP is capable of 
suppressing the effects of Aβ1-42 induced phosphorylation of ERK 1/2 
with little to no additional phosphorylation from ALP as shown with the 
20 nM ALP treatment groups. 
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Figure 3.7 Azelnidipine suppressed Aβ-induced phosphorylation of ERK p42 in bEnd.3 
cells 
bEnd.3 cells were treated with 20 nM ALP for 4 hours, 5 μM Aβ1-42 for 15 minutes, both ALP and 
Aβ1-42 or neither compound (Control) to yield a total of four data sets. The phosphorylation level 
of ERK p42 was quantified by measuring the protein expression levels of both ERK p42 and p-
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ERK p42. The data is expressed as a fraction percentages of control group with the mean ± SD 
from four independent experiments reported (* p<0.05, *** p<0.001, comparing with control 
group) (oo p<0.01, ooo p<0.001, comparing with 5 μM Aβ1-42 treatment only group). 
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Figure 3.8 Azelnidipine suppressed Aβ-induced phosphorylation of ERK p44 in bEnd.3 
cells 
bEnd.3 cells were treated with 20 nM ALP for 4 hours, 5 μM Aβ1-42 for 15 minutes, both ALP and 
Aβ1-42 or neither compound (Control) to yield a total of four data sets. The phosphorylation level 
of ERK p44 was quantified by measuring the protein expression levels of both ERK p42 and p-
ERK p42. The data is expressed as a fraction percentages of control group with the mean ± SD 
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from four independent experiments reported (** p<0.01, comparing with control group) (oo 
p<0.01, ooo p<0.001, comparing with 5 μM Aβ1-42 treatment only group). 
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3.3 Azelnidipine Suppressed Aβ-induced Phosphorylation 
of cPLA2 in bEnd.3 Cells 
Just as in ERK 1/2, we did a starving time-course study for cPLA2 
phosphorylation.  Unlike ERK 1/2, the ratio of p-cPLA2/cPLA2 showed 
little change with respect to starving time (Figure 3.11).  Western blot 
analysis showed that with 30 minutes starving time, p-cPLA2 expression 
was lowest in bEnd.3 cells, but the decrease was only ~20% compared 
to the control group. All other starving times show no significant 
difference between starving groups and control group.    The cells were 
starved for 24 hours in order to be consistent with the ERK 1/2 
experiments.  An Aβ1-42 treatment time-course study was also 
performed which showed there was a substantial increase in the 
phosphorylation of cPLA2 at 15 minutes, 4 hours and 8 hours.(Figure 
3.12) 
Initially, a 15 minute Aβ1-42 treatment time was used for cPLA2 
phosphorylation experiments, however there was no significant 
difference between the control group with no compound treatment and 
the Aβ1-42 group with 15 minutes 5 μM Aβ1-42 treatment. As a result, the 
experiment was repeated with 30 minutes 5 μM Aβ1-42 treatment and an 
increase of approximately 1.5-fold of cPLA2 phosphorylation was 
observed for bEnd.3 cells when compared to the control group (Figure 
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3.13, data contributed by both Andrey Tsoy and Tao Teng).  bEnd.3 cells 
with ALP pretreatment prior to Aβ1-42 treatment or ALP treatment alone 
showed no difference in p-cPLA2 production.  Thus ALP is capable of 
suppressing Aβ1-42 induced phosphorylation of cPLA2. 
 
 
 
 
 
38 
 
 Figure 3.9 Starving time-course study on cPLA2 phosphorylation in bEnd.3 cells 
bEnd.3 cells were starved over a 24 hour period, p-cPLA2 level was measured periodically. The 
protein expression level was quantified by western blot analysis. The data is expressed as a 
fraction percentages of the control group with box plot from three independent experiments 
reported (* p<0.05, ** p<0.01, comparing with non-starving group). 
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Figure 3.10 Aβ treatment time course study on cPLA2 phosphorylation in bEnd.3 cells 
bEnd.3 cells were treated with 5 μM Aβ1-42 over a 22 hour period. p-cPLA2 level was measured 
periodically. The protein expression level was quantified by western blot analysis. The data is 
expressed as true values from a single trial. 
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Figure 3.11 Azelnidipine suppressed Aβ-induced phosphorylation of cPLA2 in bEnd.3 
cells 
bEnd.3 cells were treated with 20nM ALP for 4 hours, 5 μM Aβ1-42 for 30 minutes, both ALP and 
Aβ1-42 or neither compound (Control) to yield a total of four data sets. The protein expression 
level was quantified by western blot analysis. The data is expressed as a fraction percentage of 
the control group with mean ± SD from three independent experiments reported (** p<0.01, 
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comparing with control group) (oo p<0.01, ooo p<0.001, comparing with 5 μM Aβ1-42 treatment 
only group) (data contributed by both Andrey Tsoy and Tao Teng). 
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3.4 Azelnidipine Suppresses Aβ-induced translocation 
of NF-κB in bEnd.3 Cells 
Translocation of NF-κB into the nucleus has been shown to induce the 
transcription of pro-inflammatory genes within endothelial cells as a 
result of Aβ1-42 oligomerization.  To test the effects of ALP on Aβ-induced 
NF-κB translocation, p65 subunit of NF-κB was labeled for 
immunofluorescence. Data showed that incubating bEnd.3 cells with 5 
µM Aβ1-42 for 2 hours led to an increase in translocation of NF-κB into 
cell nuclei.  This effect was reduced by 35% when the cell cultures were 
pretreated with 20 nM ALP for 4 hours (Figures 3.3 and 3.4).  A positive 
control group using TNF-α (instead of Aβ1-42) was employed to verify 
this technique.  The results showed that treating with 100 ng/ml TNF-α 
led to a significant increase in NF-κB translocation into the cell nuclei, 
similar to that of the Aβ1-42 treatment group (Figures 3.3 and 3.4). We 
also tested the effect of ALP alone, bEnd.3 cells pre-treated with 20 nM 
ALP for 4 hours showed no significant differences in NF-κB translocation 
when compared to the control group (Figures 3.3 and 3.4). Indeed, ALP 
suppresses the Aβ1-42-induced translocation of NF-κB within bEnd.3 cells. 
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 Figure 3.12 Effect of ALP on Aβ-induced NF-κB translocation in bEnd.3 cells 
bEnd.3 cells were treated with 20 nM ALP, 5 μM Aβ1-42, both ALP and Aβ1-42, neither compound 
(Control) or 100 ng/ml TNF-α (positive control) to yield a total of five data sets. The ratio of NF-
κB translocation was quantified by dividing NF-κB p65 subunit intensity inside cell nucleus by 
intracellular NF-κB p65 subunit intensity. The data is expressed with the mean ± SD from four 
independent experiments reported (* p<0.05, ** p<0.01, comparing with control group) (o 
p<0.05, comparing with 5 μM Aβ1-42 treatment only group). 
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 Figure 3.13 Representative immunofluorescent images of NF-κB p65 subunit and 
nucleus staining in bEnd.3 cells 
Nucleus staining are represented in red color and NF-κB p65 subunit are represented in green 
color. The merged images were obtained by combining the nucleus staining and NF-κB p65 
subunit of the same image. Compared to control (top images), Aβ increased translocation ratio 
of NF-κB (upper mid) which was suppressed by 20 nM Azelnidipine pretreatment (middle). 20 
nM Azelnidipine pretreatment did not affect NF-κB translocation ratio (lower mid). TNF-α 
treatment group served as a positive control group (bottom). 
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Chapter 4 Discussion 
ALP is a dihydropyridine compound with anti-inflammatory properties 
as a calcium channel blocker and has been used to treat patients with 
hypertension.  Reported here is an extensive study of ALP as a potential 
treatment to alleviate the inflammatory and oxidative stress effects of 
Alzheimer’s disease.   The data presented shows that ALP is capable of 
suppressing the production of ROS, the phosphorylation of ERK 1/2, 
cPLA2 and the translocation of NF-κB within bEnd.3 endothelial cells that 
occurs as a result of Aβ1-42 oligomerization.  Taking the 
signaling/activation pathway into account we will investigate the 
mechanism by which ALP reduces the cytotoxic effects of Aβ1-42.  
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 Figure 4.1 Schematic of relative pathways 
Aβ1-42 combines with RAGE which triggers NADPH p47phox subunit translocation and activates 
NADPH pathway. The ROS productions created through NADPH pathway further activates ERK 
1/2 and cPLA2 phosphorylation. ALP shows a competitive combination effect to RAGE with Aβ1-
42, also suppresses activation of downstream pathway. Aβ1-42 also initializes NF-κB translocation 
into cell nucleus which is attenuated by ALP. There also might be a cross-talk between ERK 1/2 
and NF-κB. 
Our data indicated that ROS production induced by Aβ was 
significantly suppressed by ALP in bEnd.3 cells (Figure 3.2). Also, we 
have data shows that ALP abrogates Aβ-induced co-localization between 
the cytosolic (p47-phox) and membrane (gp91-phox) subunits of 
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NADPH oxidase (data not shown). We also present data for ALP 
suppression of Aβ-induced activation of ERK 1/2 (Figure 3.9 & Figure 
3.10) and cPLA2 phosphorylation in bEnd.3 cells, data also shows ALP 
significantly suppressed phosphorylation of cPLA2 (Figure 3.13). All 
these evidences suggest that ALP may attenuate Aβ-induced co-
localization of NADPH oxidase gp91-phox and p47-phox subunits and its 
downstream pathway, including ROS generation, ERK activation and 
cPLA2 phosphorylation. 
It is interesting that when we did time-course study on Aβ-induced 
phosphorylation of ERK 1/2 and cPLA2, we found that cPLA2 gave two 
responses at 15-30 minutes and 4-8 hours (Figure 3.12), but ERK 1/2 
had only one response at ~15 minutes (Figure 3.7 & Figure 3.8). This 
likely means that cPLA2 phosphorylation occurs via a different pathway 
at times greater than 30 min after ERK 1/2 activation.  Previous reports 
have shown that oxidative stress up-regulates the NMDAR on bEnd.3 
cells (Betzen et al., 2009). Also, NMDA evokes a Ca2+ increase in 
neurons which contributes to ROS production and cPLA2 phosphorylation 
(Shelat et al., 2008).  This may also happen in cerebral endothelial cells 
explaining the additional phosphorylation of cPLA2 at 4-8 hours.  
Furthermore, Aβ has been shown to alter the concentration of 
intracellular Ca2+ in neurons and astrocytes (Sberna et al., 1997, 
Abramov et al., 2004, Niu et al., 2009, Rossner et al., 1997). Aβ may 
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have a similar effect on cerebral endothelial cells which would explain 
the ROS suppression properties of ALP shown here.  Indeed, ALP may 
attenuate phosphorylation of cPLA2 by blocking Ca2+ channels. 
Previous data suggests the receptor for advanced glycation 
endproducts (RAGE) plays an important role in Aβ-induced NADPH 
oxidase complex assembling, ROS generation, subsequent activation of 
ERK pathway and cPLA2 phosphorylation in bEnd.3 cells (Askarova et al., 
2011a). Our data also indicates that ALP competes with Aβ for binding 
to RAGE (not shown). 
In bEnd.3 cells, NF-κB activation induced by cytokines has been 
reported (Menden et al., 2013, Pueyo et al., 2000). As we mentioned 
above, Aβ triggers activation of ERK 1/2 through ROS production 
induced by NADPH oxidase in bEnd.3 cells (Askarova et al., 2011b). Our 
data shows that Aβ also actives NF-κB translocation into cell nucleus in 
bEnd.3 cells and this is suppressed by ALP pretreatment (Figure 3.3 & 
Figure 3.4). So, we further postulated that there might be a cross-talk 
mechanism between ERK 1/2 and NF-κB pathways induced by Aβ in 
bEnd.3 cells. We know that the NF-κB translocation initiates from the 
activation of IκB kinase (IKK), which degrades IκB. Then NF-κB subunits 
are free to translocate to the cell nucleus and start gene transcription. 
Due to the above evidence, we suggest that ERK 1/2 is involved in Aβ-
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induced NF-κB translocation, through ERK 1/2 or ROS cross-talk with 
IKK (Menden et al., 2013). 
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Chapter 5 Conclusion and Future work 
This study shows that ALP is capable of suppressing the effect of Aβ-
induced ROS production, ERK 1/2 activation, cPLA2 phosphorylation and 
NF-κB translocation.   This study proves that ALP is capable of alleviating 
two major factors that contribute to the cytotoxicity of amyloid-β in AD, 
oxidative stress and inflammation.  This evidence suggests that ALP has 
the potential to be a pharmaceutical therapy for Alzheimer’s disease. 
Future work should include further investigation of the potential 
cross-talk between ERK 1/2, ROS and NF-κB which can be accomplished 
using specific inhibitors for ERKs and ROS.  Since cPLA2 phosphorylation 
increased at both 15 minutes and 4-8 hours, it would be beneficial to 
test the effect of ALP on phosphorylation of cPLA2 with 6 hours Aβ 
incubation in the presence of another calcium channel blocker as a 
negative control.  Also, E-selectin is involved in NF-κB activation, so it 
would be interesting to design an experiment that would test the effects 
ALP and Aβ1-42 on both E-selectin expression and the cell inflammatory 
response. 
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